Cancer Center News

CHOP researchers have identified a molecule that plays a role in post-translational modification and activation in myeloid cancers, making it a potential therapeutic target.

Collaboration among CHOP, Alex’s Lemonade Stand Foundation, the Pacific Pediatric Neuro-Oncology Consortium, and Children’s Brain Tumor Network paves the way for new collaborative models to accelerate discoveries.

CHOP and UCLA researchers have created a tool that can discover tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets.

Two recent papers from CHOP cancer researchers have advanced the understanding of treatment-resistant pediatric central nervous system tumors.

CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.

Levy traveled from Brazil and participated in a clinical trial for an oral drug that targets an NTRK gene fusion that drives cancer-cell growth.

With support from Jazz Pharmaceuticals, the grant will fund a SU2C Catalyst® Research Team led by Dr. Grohar; the team will investigate new, targeted treatments for patients 10 years and older with Ewing sarcoma.

CHOP researchers have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant.

Through collaboration with research partners, patients, foundations, and community members, we are working to defeat childhood brain cancer and find better treatments for current patients. Read about recent milestones we’ve hit to accelerate pediatric brain tumor research.

Read this case study about integrating precision medicine into the standard of care for children with thyroid cancer.